APO Research
Talk to an analyst

APO RESEARCH · REPORT

Platinum-based Antineoplastic

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Platinum-based Antineoplastic Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

30 December 2025195 pages

Choose your research edition.

Industry ResearchPlatinum-based Antineoplastic Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Platinum-based Antineoplastic Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Platinum-based Antineoplastic Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Platinum-based Antineoplastic Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Platinum-based Antineoplastic Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Platinum-based Antineoplastic market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Platinum-based Antineoplastic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Platinum-based Antineoplastic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Platinum-based Antineoplastic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Platinum-based Antineoplastic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Platinum-based Antineoplastic include ChiTaiTianQing Pharmaceutical Group, Simcere Pharmaceutical, CSPC Pharmaceutical Group, Sanofi, Novartis, MSD, Roche, Pfizer and Hengrui Medicine, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Platinum-based Antineoplastic market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Platinum-based Antineoplastic and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Platinum-based Antineoplastic sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Platinum-based Antineoplastic market size, projected growth trends, production technologies, key applications, and end-use industries.

Platinum-based Antineoplastic Segment by Company

ChiTaiTianQing Pharmaceutical Group

Simcere Pharmaceutical

CSPC Pharmaceutical Group

Sanofi

Novartis

MSD

Roche

Pfizer

Hengrui Medicine

Hansoh Pharmaceutical Group

GSK

Bristol-Myers Squibb

Abbvie

AstraZeneca

Asta Medica GmbH

Platinum-based Antineoplastic Segment by Type

Oxaliplatin

Cycloplatin

Carboplatin

Lobaplatin

Nedaplatin

Cisplatin

Platinum-based Antineoplastic Segment by Application

Targeted Therapy

Monotherapy

Combination Therapy

Platinum-based Antineoplastic Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Platinum-based Antineoplastic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Platinum-based Antineoplastic and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Platinum-based Antineoplastic.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Platinum-based Antineoplastic market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Platinum-based Antineoplastic manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Platinum-based Antineoplastic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Platinum-based Antineoplastic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Platinum-based Antineoplastic Industry Trends Table 2. Platinum-based Antineoplastic Industry Drivers Table 3. Platinum-based Antineoplastic Industry Opportunities and Challenges Table 4. Platinum-based Antineoplastic Industry Restraints Table 5. Global Platinum-based Antineoplastic Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Platinum-based Antineoplastic Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Platinum-based Antineoplastic Sales by Manufacturers (Units) & (2021-2026) Table 8. Global Platinum-based Antineoplastic Sales Market Share by Manufacturers Table 9. Global Platinum-based Antineoplastic Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Platinum-based Antineoplastic Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Platinum-based Antineoplastic Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Platinum-based Antineoplastic Manufacturers, Product Type & Application Table 13. Global Platinum-based Antineoplastic Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Platinum-based Antineoplastic by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Oxaliplatin Table 17. Major Manufacturers of Cycloplatin Table 18. Major Manufacturers of Carboplatin Table 19. Major Manufacturers of Lobaplatin Table 20. Major Manufacturers of Nedaplatin Table 21. Major Manufacturers of Cisplatin Table 22. Global Platinum-based Antineoplastic Sales by Type 2021 VS 2025 VS 2032 (Units) Table 23. Global Platinum-based Antineoplastic Sales by Type (2021-2026) & (Units) Table 24. Global Platinum-based Antineoplastic Sales by Type (2027-2032) & (Units) Table 25. Global Platinum-based Antineoplastic Sales Market Share by Type (2021-2026) Table 26. Global Platinum-based Antineoplastic Sales Market Share by Type (2027-2032) Table 27. Global Platinum-based Antineoplastic Revenue by Type 2021 VS 2025 VS 2032 (Units) Table 28. Global Platinum-based Antineoplastic Revenue by Type (2021-2026) & (Units) Table 29. Global Platinum-based Antineoplastic Revenue by Type (2027-2032) & (Units) Table 30. Global Platinum-based Antineoplastic Revenue Market Share by Type (2021-2026) Table 31. Global Platinum-based Antineoplastic Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Targeted Therapy Table 33. Major Manufacturers of Monotherapy Table 34. Major Manufacturers of Combination Therapy Table 35. Global Platinum-based Antineoplastic Sales by Application 2021 VS 2025 VS 2032 (Units) Table 36. Global Platinum-based Antineoplastic Sales by Application (2021-2026) & (Units) Table 37. Global Platinum-based Antineoplastic Sales by Application (2027-2032) & (Units) Table 38. Global Platinum-based Antineoplastic Sales Market Share by Application (2021-2026) Table 39. Global Platinum-based Antineoplastic Sales Market Share by Application (2027-2032) Table 40. Global Platinum-based Antineoplastic Revenue by Application 2021 VS 2025 VS 2032 (Units) Table 41. Global Platinum-based Antineoplastic Revenue by Application (2021-2026) & (Units) Table 42. Global Platinum-based Antineoplastic Revenue by Application (2027-2032) & (Units) Table 43. Global Platinum-based Antineoplastic Revenue Market Share by Application (2021-2026) Table 44. Global Platinum-based Antineoplastic Revenue Market Share by Application (2027-2032) Table 45. Global Platinum-based Antineoplastic Sales by Region: 2021 VS 2025 VS 2032 (Units) Table 46. Global Platinum-based Antineoplastic Sales by Region (2021-2026) & (Units) Table 47. Global Platinum-based Antineoplastic Sales Market Share by Region (2021-2026) Table 48. Global Platinum-based Antineoplastic Sales Forecasted by Region (2027-2032) & (Units) Table 49. Global Platinum-based Antineoplastic Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Platinum-based Antineoplastic Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 51. North America Platinum-based Antineoplastic Sales by Country (2021-2026) & (Units) Table 52. North America Platinum-based Antineoplastic Sales by Country (2027-2032) & (Units) Table 53. Europe Platinum-based Antineoplastic Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 54. Europe Platinum-based Antineoplastic Sales by Country (2021-2026) & (Units) Table 55. Europe Platinum-based Antineoplastic Sales by Country (2027-2032) & (Units) Table 56. Asia Pacific Platinum-based Antineoplastic Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 57. Asia Pacific Platinum-based Antineoplastic Sales by Country (2021-2026) & (Units) Table 58. Asia Pacific Platinum-based Antineoplastic Sales by Country (2027-2032) & (Units) Table 59. South America, Middle East and Africa Platinum-based Antineoplastic Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 60. South America, Middle East and Africa Platinum-based Antineoplastic Sales by Country (2021-2026) & (Units) Table 61. South America, Middle East and Africa Platinum-based Antineoplastic Sales by Country (2027-2032) & (Units) Table 62. Global Platinum-based Antineoplastic Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Platinum-based Antineoplastic Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Platinum-based Antineoplastic Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Platinum-based Antineoplastic Revenue Market Share by Region (2021-2026) Table 66. Global Platinum-based Antineoplastic Revenue Market Share by Region (2027-2032) Table 67. ChiTaiTianQing Pharmaceutical Group Company Information Table 68. ChiTaiTianQing Pharmaceutical Group Business Overview Table 69. ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio Table 71. ChiTaiTianQing Pharmaceutical Group Recent Development Table 72. Simcere Pharmaceutical Company Information Table 73. Simcere Pharmaceutical Business Overview Table 74. Simcere Pharmaceutical Platinum-based Antineoplastic Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Simcere Pharmaceutical Platinum-based Antineoplastic Product Portfolio Table 76. Simcere Pharmaceutical Recent Development Table 77. CSPC Pharmaceutical Group Company Information Table 78. CSPC Pharmaceutical Group Business Overview Table 79. CSPC Pharmaceutical Group Platinum-based Antineoplastic Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. CSPC Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio Table 81. CSPC Pharmaceutical Group Recent Development Table 82. Sanofi Company Information Table 83. Sanofi Business Overview Table 84. Sanofi Platinum-based Antineoplastic Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Sanofi Platinum-based Antineoplastic Product Portfolio Table 86. Sanofi Recent Development Table 87. Novartis Company Information Table 88. Novartis Business Overview Table 89. Novartis Platinum-based Antineoplastic Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Novartis Platinum-based Antineoplastic Product Portfolio Table 91. Novartis Recent Development Table 92. MSD Company Information Table 93. MSD Business Overview Table 94. MSD Platinum-based Antineoplastic Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. MSD Platinum-based Antineoplastic Product Portfolio Table 96. MSD Recent Development Table 97. Roche Company Information Table 98. Roche Business Overview Table 99. Roche Platinum-based Antineoplastic Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Roche Platinum-based Antineoplastic Product Portfolio Table 101. Roche Recent Development Table 102. Pfizer Company Information Table 103. Pfizer Business Overview Table 104. Pfizer Platinum-based Antineoplastic Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Pfizer Platinum-based Antineoplastic Product Portfolio Table 106. Pfizer Recent Development Table 107. Hengrui Medicine Company Information Table 108. Hengrui Medicine Business Overview Table 109. Hengrui Medicine Platinum-based Antineoplastic Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Hengrui Medicine Platinum-based Antineoplastic Product Portfolio Table 111. Hengrui Medicine Recent Development Table 112. Hansoh Pharmaceutical Group Company Information Table 113. Hansoh Pharmaceutical Group Business Overview Table 114. Hansoh Pharmaceutical Group Platinum-based Antineoplastic Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Hansoh Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio Table 116. Hansoh Pharmaceutical Group Recent Development Table 117. GSK Company Information Table 118. GSK Business Overview Table 119. GSK Platinum-based Antineoplastic Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. GSK Platinum-based Antineoplastic Product Portfolio Table 121. GSK Recent Development Table 122. Bristol-Myers Squibb Company Information Table 123. Bristol-Myers Squibb Business Overview Table 124. Bristol-Myers Squibb Platinum-based Antineoplastic Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Bristol-Myers Squibb Platinum-based Antineoplastic Product Portfolio Table 126. Bristol-Myers Squibb Recent Development Table 127. Abbvie Company Information Table 128. Abbvie Business Overview Table 129. Abbvie Platinum-based Antineoplastic Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. Abbvie Platinum-based Antineoplastic Product Portfolio Table 131. Abbvie Recent Development Table 132. AstraZeneca Company Information Table 133. AstraZeneca Business Overview Table 134. AstraZeneca Platinum-based Antineoplastic Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. AstraZeneca Platinum-based Antineoplastic Product Portfolio Table 136. AstraZeneca Recent Development Table 137. Asta Medica GmbH Company Information Table 138. Asta Medica GmbH Business Overview Table 139. Asta Medica GmbH Platinum-based Antineoplastic Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 140. Asta Medica GmbH Platinum-based Antineoplastic Product Portfolio Table 141. Asta Medica GmbH Recent Development Table 142. Key Raw Materials Table 143. Raw Materials Key Suppliers Table 144. Platinum-based Antineoplastic Distributors List Table 145. Platinum-based Antineoplastic Customers List Table 146. Research Programs/Design for This Report Table 147. Authors List of This Report Table 148. Secondary Sources Table 149. Primary Sources List of Figures Figure 1. Platinum-based Antineoplastic Product Image Figure 2. Global Platinum-based Antineoplastic Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Platinum-based Antineoplastic Market Size (2021-2032) & (US$ Million) Figure 4. Global Platinum-based Antineoplastic Sales (2021-2032) & (Units) Figure 5. Global Platinum-based Antineoplastic Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Platinum-based Antineoplastic Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Oxaliplatin Image Figure 9. Cycloplatin Image Figure 10. Carboplatin Image Figure 11. Lobaplatin Image Figure 12. Nedaplatin Image Figure 13. Cisplatin Image Figure 14. Global Platinum-based Antineoplastic Sales by Type (2021 VS 2025 VS 2032) & (Units) Figure 15. Global Platinum-based Antineoplastic Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Platinum-based Antineoplastic Sales Market Share by Type (2021-2032) Figure 17. Global Platinum-based Antineoplastic Revenue by Type (2021 VS 2025 VS 2032) & (Units) Figure 18. Global Platinum-based Antineoplastic Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Platinum-based Antineoplastic Revenue Market Share by Type (2021-2032) Figure 20. Targeted Therapy Image Figure 21. Monotherapy Image Figure 22. Combination Therapy Image Figure 23. Global Platinum-based Antineoplastic Sales by Application (2021 VS 2025 VS 2032) & (Units) Figure 24. Global Platinum-based Antineoplastic Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Platinum-based Antineoplastic Sales Market Share by Application (2021-2032) Figure 26. Global Platinum-based Antineoplastic Revenue by Application (2021 VS 2025 VS 2032) & (Units) Figure 27. Global Platinum-based Antineoplastic Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Platinum-based Antineoplastic Revenue Market Share by Application (2021-2032) Figure 29. North America Platinum-based Antineoplastic Sales and Growth Rate (2021-2032) & (Units) Figure 30. North America Platinum-based Antineoplastic Sales Market Share by Country (2021-2032) Figure 31. U.S. Platinum-based Antineoplastic Sales and Growth Rate (2021-2032) & (Units) Figure 32. Canada Platinum-based Antineoplastic Sales and Growth Rate (2021-2032) & (Units) Figure 33. Mexico Platinum-based Antineoplastic Sales and Growth Rate (2021-2032) & (Units) Figure 34. Europe Platinum-based Antineoplastic Sales and Growth Rate (2021-2032) & (Units) Figure 35. Europe Platinum-based Antineoplastic Sales Market Share by Country (2021-2032) Figure 36. Germany Platinum-based Antineoplastic Sales and Growth Rate (2021-2032) & (Units) Figure 37. France Platinum-based Antineoplastic Sales and Growth Rate (2021-2032) & (Units) Figure 38. U.K. Platinum-based Antineoplastic Sales and Growth Rate (2021-2032) & (Units) Figure 39. Italy Platinum-based Antineoplastic Sales and Growth Rate (2021-2032) & (Units) Figure 40. Netherlands Platinum-based Antineoplastic Sales and Growth Rate (2021-2032) & (Units) Figure 41. Asia Pacific Platinum-based Antineoplastic Sales and Growth Rate (2021-2032) & (Units) Figure 42. Asia Pacific Platinum-based Antineoplastic Sales Market Share by Country (2021-2032) Figure 43. China Platinum-based Antineoplastic Sales and Growth Rate (2021-2032) & (Units) Figure 44. Japan Platinum-based Antineoplastic Sales and Growth Rate (2021-2032) & (Units) Figure 45. South Korea Platinum-based Antineoplastic Sales and Growth Rate (2021-2032) & (Units) Figure 46. Southeast Asia Platinum-based Antineoplastic Sales and Growth Rate (2021-2032) & (Units) Figure 47. India Platinum-based Antineoplastic Sales and Growth Rate (2021-2032) & (Units) Figure 48. Australia Platinum-based Antineoplastic Sales and Growth Rate (2021-2032) & (Units) Figure 49. South America, Middle East and Africa Platinum-based Antineoplastic Sales and Growth Rate (2021-2032) & (Units) Figure 50. South America, Middle East and Africa Platinum-based Antineoplastic Sales Market Share by Country (2021-2032) Figure 51. Brazil Platinum-based Antineoplastic Sales and Growth Rate (2021-2032) & (Units) Figure 52. South Africa Platinum-based Antineoplastic Sales and Growth Rate (2021-2032) & (Units) Figure 53. Saudi Arabia Platinum-based Antineoplastic Sales and Growth Rate (2021-2032) & (Units) Figure 54. Turkey Platinum-based Antineoplastic Sales and Growth Rate (2021-2032) & (Units) Figure 55. Argentina Platinum-based Antineoplastic Sales and Growth Rate (2021-2032) & (Units) Figure 56. UAE Platinum-based Antineoplastic Sales and Growth Rate (2021-2032) & (Units) Figure 57. Egypt Platinum-based Antineoplastic Sales and Growth Rate (2021-2032) & (Units) Figure 58. Chile Platinum-based Antineoplastic Sales and Growth Rate (2021-2032) & (Units) Figure 59. Global Platinum-based Antineoplastic Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Platinum-based Antineoplastic Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Platinum-based Antineoplastic Revenue (2021-2032) & (US$ Million) Figure 62. North America Platinum-based Antineoplastic Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Platinum-based Antineoplastic Revenue (2021-2032) & (US$ Million) Figure 64. Europe Platinum-based Antineoplastic Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Platinum-based Antineoplastic Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Platinum-based Antineoplastic Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Platinum-based Antineoplastic Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Platinum-based Antineoplastic Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Platinum-based Antineoplastic Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Platinum-based Antineoplastic Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Oxaliplatin
  • Cycloplatin
  • Carboplatin
  • Lobaplatin
  • Nedaplatin
  • Cisplatin
Applications
  • Targeted Therapy
  • Monotherapy
  • Combination Therapy
Companies covered
  • ChiTaiTianQing Pharmaceutical Group
  • Simcere Pharmaceutical
  • CSPC Pharmaceutical Group
  • Sanofi
  • Novartis
  • MSD
  • Roche
  • Pfizer
  • Hengrui Medicine
  • Hansoh Pharmaceutical Group
  • GSK
  • Bristol-Myers Squibb
  • Abbvie
  • AstraZeneca
  • Asta Medica GmbH

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Platinum-based Antineoplastic Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Platinum-based Antineoplastic Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Platinum-based Antineoplastic Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Platinum-based Antineoplastic Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Platinum-based Antineoplastic Market Dynamics
  1. 2.1 Platinum-based Antineoplastic Industry Trends
  2. 2.2 Platinum-based Antineoplastic Industry Drivers
  3. 2.3 Platinum-based Antineoplastic Industry Opportunities and Challenges
  4. 2.4 Platinum-based Antineoplastic Industry Restraints
3 Platinum-based Antineoplastic Market by Manufacturers
  1. 3.1 Global Platinum-based Antineoplastic Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Platinum-based Antineoplastic Sales by Manufacturers (2021-2026)
  3. 3.3 Global Platinum-based Antineoplastic Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Platinum-based Antineoplastic Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Platinum-based Antineoplastic Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Platinum-based Antineoplastic Manufacturers, Product Type & Application
  7. 3.7 Global Platinum-based Antineoplastic Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Platinum-based Antineoplastic Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Platinum-based Antineoplastic Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Platinum-based Antineoplastic Tier 1, Tier 2, and Tier 3
4 Platinum-based Antineoplastic Market by Type
  1. 4.1 Platinum-based Antineoplastic Type Introduction
  2. 4.1.1 Oxaliplatin
  3. 4.1.2 Cycloplatin
  4. 4.1.3 Carboplatin
  5. 4.1.4 Lobaplatin
  6. 4.1.5 Nedaplatin
  7. 4.1.6 Cisplatin
  8. 4.2 Global Platinum-based Antineoplastic Sales by Type
  9. 4.2.1 Global Platinum-based Antineoplastic Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Platinum-based Antineoplastic Sales by Type (2021-2032)
  11. 4.2.3 Global Platinum-based Antineoplastic Sales Market Share by Type (2021-2032)
  12. 4.3 Global Platinum-based Antineoplastic Revenue by Type
  13. 4.3.1 Global Platinum-based Antineoplastic Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Platinum-based Antineoplastic Revenue by Type (2021-2032)
  15. 4.3.3 Global Platinum-based Antineoplastic Revenue Market Share by Type (2021-2032)
5 Platinum-based Antineoplastic Market by Application
  1. 5.1 Platinum-based Antineoplastic Application Introduction
  2. 5.1.1 Targeted Therapy
  3. 5.1.2 Monotherapy
  4. 5.1.3 Combination Therapy
  5. 5.2 Global Platinum-based Antineoplastic Sales by Application
  6. 5.2.1 Global Platinum-based Antineoplastic Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Platinum-based Antineoplastic Sales by Application (2021-2032)
  8. 5.2.3 Global Platinum-based Antineoplastic Sales Market Share by Application (2021-2032)
  9. 5.3 Global Platinum-based Antineoplastic Revenue by Application
  10. 5.3.1 Global Platinum-based Antineoplastic Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Platinum-based Antineoplastic Revenue by Application (2021-2032)
  12. 5.3.3 Global Platinum-based Antineoplastic Revenue Market Share by Application (2021-2032)
6 Global Platinum-based Antineoplastic Sales by Region
  1. 6.1 Global Platinum-based Antineoplastic Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Platinum-based Antineoplastic Sales by Region (2021-2032)
  3. 6.2.1 Global Platinum-based Antineoplastic Sales by Region (2021-2026)
  4. 6.2.2 Global Platinum-based Antineoplastic Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Platinum-based Antineoplastic Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Platinum-based Antineoplastic Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Platinum-based Antineoplastic Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Platinum-based Antineoplastic Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Platinum-based Antineoplastic Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Platinum-based Antineoplastic Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Platinum-based Antineoplastic Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Platinum-based Antineoplastic Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Platinum-based Antineoplastic Revenue by Region
  1. 7.1 Global Platinum-based Antineoplastic Revenue by Region
  2. 7.1.1 Global Platinum-based Antineoplastic Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Platinum-based Antineoplastic Revenue by Region (2021-2026)
  4. 7.1.3 Global Platinum-based Antineoplastic Revenue by Region (2027-2032)
  5. 7.1.4 Global Platinum-based Antineoplastic Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Platinum-based Antineoplastic Revenue (2021-2032)
  8. 7.2.2 North America Platinum-based Antineoplastic Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Platinum-based Antineoplastic Revenue (2021-2032)
  11. 7.3.2 Europe Platinum-based Antineoplastic Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Platinum-based Antineoplastic Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Platinum-based Antineoplastic Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Platinum-based Antineoplastic Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Platinum-based Antineoplastic Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 ChiTaiTianQing Pharmaceutical Group
  2. 8.1.1 ChiTaiTianQing Pharmaceutical Group Company Information
  3. 8.1.2 ChiTaiTianQing Pharmaceutical Group Business Overview
  4. 8.1.3 ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio
  6. 8.1.5 ChiTaiTianQing Pharmaceutical Group Recent Developments
  7. 8.2 Simcere Pharmaceutical
  8. 8.2.1 Simcere Pharmaceutical Company Information
  9. 8.2.2 Simcere Pharmaceutical Business Overview
  10. 8.2.3 Simcere Pharmaceutical Platinum-based Antineoplastic Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Simcere Pharmaceutical Platinum-based Antineoplastic Product Portfolio
  12. 8.2.5 Simcere Pharmaceutical Recent Developments
  13. 8.3 CSPC Pharmaceutical Group
  14. 8.3.1 CSPC Pharmaceutical Group Company Information
  15. 8.3.2 CSPC Pharmaceutical Group Business Overview
  16. 8.3.3 CSPC Pharmaceutical Group Platinum-based Antineoplastic Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 CSPC Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio
  18. 8.3.5 CSPC Pharmaceutical Group Recent Developments
  19. 8.4 Sanofi
  20. 8.4.1 Sanofi Company Information
  21. 8.4.2 Sanofi Business Overview
  22. 8.4.3 Sanofi Platinum-based Antineoplastic Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sanofi Platinum-based Antineoplastic Product Portfolio
  24. 8.4.5 Sanofi Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Platinum-based Antineoplastic Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Platinum-based Antineoplastic Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 MSD
  32. 8.6.1 MSD Company Information
  33. 8.6.2 MSD Business Overview
  34. 8.6.3 MSD Platinum-based Antineoplastic Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 MSD Platinum-based Antineoplastic Product Portfolio
  36. 8.6.5 MSD Recent Developments
  37. 8.7 Roche
  38. 8.7.1 Roche Company Information
  39. 8.7.2 Roche Business Overview
  40. 8.7.3 Roche Platinum-based Antineoplastic Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Roche Platinum-based Antineoplastic Product Portfolio
  42. 8.7.5 Roche Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Platinum-based Antineoplastic Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Platinum-based Antineoplastic Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 Hengrui Medicine
  50. 8.9.1 Hengrui Medicine Company Information
  51. 8.9.2 Hengrui Medicine Business Overview
  52. 8.9.3 Hengrui Medicine Platinum-based Antineoplastic Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Hengrui Medicine Platinum-based Antineoplastic Product Portfolio
  54. 8.9.5 Hengrui Medicine Recent Developments
  55. 8.10 Hansoh Pharmaceutical Group
  56. 8.10.1 Hansoh Pharmaceutical Group Company Information
  57. 8.10.2 Hansoh Pharmaceutical Group Business Overview
  58. 8.10.3 Hansoh Pharmaceutical Group Platinum-based Antineoplastic Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Hansoh Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio
  60. 8.10.5 Hansoh Pharmaceutical Group Recent Developments
  61. 8.11 GSK
  62. 8.11.1 GSK Company Information
  63. 8.11.2 GSK Business Overview
  64. 8.11.3 GSK Platinum-based Antineoplastic Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 GSK Platinum-based Antineoplastic Product Portfolio
  66. 8.11.5 GSK Recent Developments
  67. 8.12 Bristol-Myers Squibb
  68. 8.12.1 Bristol-Myers Squibb Company Information
  69. 8.12.2 Bristol-Myers Squibb Business Overview
  70. 8.12.3 Bristol-Myers Squibb Platinum-based Antineoplastic Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bristol-Myers Squibb Platinum-based Antineoplastic Product Portfolio
  72. 8.12.5 Bristol-Myers Squibb Recent Developments
  73. 8.13 Abbvie
  74. 8.13.1 Abbvie Company Information
  75. 8.13.2 Abbvie Business Overview
  76. 8.13.3 Abbvie Platinum-based Antineoplastic Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Abbvie Platinum-based Antineoplastic Product Portfolio
  78. 8.13.5 Abbvie Recent Developments
  79. 8.14 AstraZeneca
  80. 8.14.1 AstraZeneca Company Information
  81. 8.14.2 AstraZeneca Business Overview
  82. 8.14.3 AstraZeneca Platinum-based Antineoplastic Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 AstraZeneca Platinum-based Antineoplastic Product Portfolio
  84. 8.14.5 AstraZeneca Recent Developments
  85. 8.15 Asta Medica GmbH
  86. 8.15.1 Asta Medica GmbH Company Information
  87. 8.15.2 Asta Medica GmbH Business Overview
  88. 8.15.3 Asta Medica GmbH Platinum-based Antineoplastic Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Asta Medica GmbH Platinum-based Antineoplastic Product Portfolio
  90. 8.15.5 Asta Medica GmbH Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Platinum-based Antineoplastic Value Chain Analysis
  2. 9.1.1 Platinum-based Antineoplastic Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Platinum-based Antineoplastic Production Mode & Process
  6. 9.2 Platinum-based Antineoplastic Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Platinum-based Antineoplastic Distributors
  9. 9.2.3 Platinum-based Antineoplastic Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst